Beta-amyloid peptides enhance the proliferative response of activated CD4 +CD28 + lymphocytes from alzheimer disease patients and from healthy elderly

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Jóźwik, Agnieszka ^a,c   Landowski, Jerzy ^a   Bidzan, Leszek ^a   Fülop, Tamas ^b   Bryl, Ewa ^a   Witkowski, Jacek M ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF SHERBROOKE   (Canada)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CD69 ANTIGEN; CD28 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ADULT; AGED; ALZHEIMER DISEASE; ANTIGEN EXPRESSION; ARTICLE; CD4+ CD28+ T LYMPHOCYTE; CELL CYCLE; CELL DIVISION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; NORMAL HUMAN; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; DRUG EFFECT; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIGENS, CD28; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTORS;

EID: 84858054256     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033276     Document Type: Article

References (59)

1. Britschgi M, Wyss-Coray T, (2007) Systemic and acquired immune responses in Alzheimer's disease. Int Rev Neurobiol 82: 205-33.:205-233.
2. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
3. McGeer EG, McGeer PL, (1999) Brain inflammation in Alzheimer disease and the therapeutic implications. Curr Pharm Des 5: 821-836.
4. Querfurth HW, LaFerla FM, (2010) Alzheimer's disease. N Engl J Med 362: 329-344.
5. Finch CE, Morgan TE, (2007) Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr Alzheimer Res 4: 185-189.
6. Bonotis K, Krikki E, Holeva V, Aggouridaki C, Costa V, et al. (2008) Systemic immune aberrations in Alzheimer's disease patients. J Neuroimmunol 193: 183-187.
7. Miscia S, Ciccocioppo F, Lanuti P, Velluto L, Bascelli A, et al. (2009) Abeta(1-42) stimulated T cells express P-PKC-delta and P-PKC-zeta in Alzheimer disease. Neurobiol Aging 30: 394-406.
8. Liu YJ, Guo DW, Tian L, Shang DS, Zhao WD, et al. (2010) Peripheral T cells derived from Alzheimer's disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-alpha-dependent. Neurobiol Aging 31: 175-188.
9. Togo T, Akiyama H, Iseki E, Kondo H, Ikeda K, et al. (2002) Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol 124: 83-92.
10. Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian E, et al. (2009) Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J Alzheimers Dis 17: 91-103.
11. Baril L, Nicolas L, Croisile B, Crozier P, Hessler C, et al. (2004) Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects. Neurosci Lett 355: 226-230.
12. Trieb K, Ransmayr G, Sgonc R, Lassmann H, Grubeck-Loebenstein B, (1996) APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol Aging 17: 541-547.
13. Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, et al. (2003) Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 112: 415-422.
14. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, et al. (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6: 734-746.
15. Ligthart GJ, Corberand JX, Fournier C, Galanaud P, Hijmans W, et al. (1984) Admission criteria for immunogerontological studies in man: the SENIEUR protocol. Mech Ageing Dev 28: 47-55.
16. Galasko D, Klauber MR, Hofstetter CR, Salmon DP, Lasker B, et al. (1990) The Mini-Mental State Examination in the early diagnosis of Alzheimer's disease. Arch Neurol 47: 49-52.
17. Bryl E, Daca A, Jozwik A, Witkowski JM, (2009) Human CD4low CD25high regulatory T cells indiscriminately kill autologous activated T cells. Immunology 128: e287-e295.
18. Witkowski JM, (2008) Advanced application of CFSE for cellular tracking. Curr Protoc Cytom Chapter 9: Unit9.
19. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, et al. (2010) Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010 pii: 986310.:986310.
20. Teixeira AL, Reis HJ, Coelho FM, Carneiro DS, Teixeira MM, et al. (2008) All-or-nothing type biphasic cytokine production of human lymphocytes after exposure to Alzheimer's beta-amyloid peptide. Biol Psychiatry 64: 891-895.
21. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177.
22. Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, et al. (2000) Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann N Y Acad Sci 920: 328-331.
23. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, et al. (2000) Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48: 567-579.
24. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, et al. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982.
25. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985.
26. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46-54.
27. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562.
28. Masliah E, Hansen L, Adame A, Crews L, Bard F, et al. (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64: 129-131.
29. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, et al. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9: 448-452.
30. Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F, (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14: 11-20.
31. Giubilei F, Antonini G, Montesperelli C, Sepe-Monti M, Cannoni S, et al. (2003) T cell response to amyloid-beta and to mitochondrial antigens in Alzheimer's disease. Dement Geriatr Cogn Disord 16: 35-38.
32. Trieb K, Ransmayr G, Sgonc R, Lassmann H, Grubeck-Loebenstein B, (1996) APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol Aging 17: 541-547.
33. Zota V, Nemirovsky A, Baron R, Fisher Y, Selkoe DJ, et al. (2009) HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele. J Immunol 183: 3522-3530.
34. Schmitt TL, Steger MM, Pavelka M, Grubeck-Loebenstein B, (1997) Interactions of the Alzheimer beta amyloid fragment (25-35) with peripheral blood dendritic cells. Mech Ageing Dev 94: 223-232.
35. Town T, Vendrame M, Patel A, Poetter D, DelleDonne A, et al. (2002) Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42). J Neuroimmunol 132: 49-59.
36. Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, et al. (2010) IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol 184: 5333-5343.
37. Tarkowski E, Blennow K, Wallin A, Tarkowski A, (1999) Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 19: 223-230.
38. Alvarez A, Cacabelos R, Sanpedro C, Garcia-Fantini M, Aleixandre M, (2007) Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging 28: 533-536.
39. Zuliani G, Ranzini M, Guerra G, Rossi L, Munari MR, et al. (2007) Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. J Psychiatr Res 41: 686-693.
40. Paganelli R, Di IA, Patricelli L, Ripani F, Sparvieri E, et al. (2002) Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer's disease patients. Exp Gerontol 37: 257-263.
41. Richartz E, Batra A, Simon P, Wormstall H, Bartels M, et al. (2005) Diminished production of proinflammatory cytokines in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 19: 184-188.
42. Weyand CM, Brandes JC, Schmidt D, Fulbright JW, Goronzy JJ, (1998) Functional properties of CD4+. Mech Ageing Dev 102: 131-147.
43. Komocsi A, Lamprecht P, Csernok E, Mueller A, Holl-Ulrich K, et al. (2002) Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis. Am J Pathol 160: 1717-1724.
44. Pellicano M, Bulati M, Buffa S, Barbagallo M, Di PA, et al. (2010) Systemic immune responses in Alzheimer's disease: in vitro mononuclear cell activation and cytokine production. J Alzheimers Dis 21: 181-192.
45. Manzoni C, Colombo L, Bigini P, Diana V, Cagnotto A, et al. (2011) The molecular assembly of amyloid abeta controls its neurotoxicity and binding to cellular proteins. PLoS One 6: e24909.
46. Milojevic J, Melacini G, (2011) Stoichiometry and affinity of the human serum albumin-Alzheimer's Abeta peptide interactions. Biophys J 100: 183-192.
47. Schmidt AM, Sahagan B, Nelson RB, Selmer J, Rothlein R, et al. (2009) The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Curr Opin Investig Drugs 10: 672-680.
48. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, et al. (2001) Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 171: 29-45.
49. Buchanan MM, Hutchinson M, Watkins LR, Yin H, (2010) Toll-like receptor 4 in CNS pathologies. J Neurochem 114: 13-27.
50. Gamba P, Leonarduzzi G, Tamagno E, Guglielmotto M, Testa G, et al. (2011) Interaction between 24-hydroxycholesterol, oxidative stress, and amyloid-beta in amplifying neuronal damage in Alzheimer's disease: three partners in crime. Aging Cell 10: 403-417.
51. Gonzalez-Navajas JM, Fine S, Law J, Datta SK, Nguyen KP, et al. (2010) TLR4 signaling in effector CD4+ T cells regulates TCR activation and experimental colitis in mice. J Clin Invest 120: 570-581.
52. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM, (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457: 1128-1132.
53. Kessels HW, Nguyen LN, Nabavi S, Malinow R, (2010) The prion protein as a receptor for amyloid-beta. Nature 466: E3-E4.
54. Li R, Liu D, Zanusso G, Liu T, Fayen JD, et al. (2001) The expression and potential function of cellular prion protein in human lymphocytes. Cell Immunol 207: 49-58.
55. Ingram RJ, Isaacs JD, Kaur G, Lowther DE, Reynolds CJ, et al. (2009) A role of cellular prion protein in programming T-cell cytokine responses in disease. FASEB J 23: 1672-1684.
56. Palotas A, Kalman J, Palotas M, Juhasz A, Janka Z, et al. (2002) Beta-amyloid-induced increase in the resting intracellular calcium concentration gives support to tell Alzheimer lymphocytes from control ones. Brain Res Bull 58: 203-205.
57. Politopoulou G, Seebach JD, Schmugge M, Schwarz HP, Aguzzi A, (2000) Age-related expression of the cellular prion protein in human peripheral blood leukocytes. Haematologica 85: 580-587.
58. Stieler JT, Lederer C, Bruckner MK, Wolf H, Holzer M, et al. (2001) Impairment of mitogenic activation of peripheral blood lymphocytes in Alzheimer's disease. Neuroreport 12: 3969-3972.
59. Le BN, Leurs J, Blomme W, De Deyn PP, Engelborghs S, (2010) Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients. J Alzheimers Dis 21: 291-301.